Byron Lee
YOU?
Author Swipe
View article: Supplementary Table S1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Table S1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Table S1
View article: Supplementary Figure 6 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 6 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 6
View article: Supplementary Figure 8 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 8 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 8
View article: Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Data 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
List of TCGA cases used in ATAC-seq analysis
View article: Supplementary Figure 4 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 4 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 4
View article: Supplementary Figure Legends from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure Legends from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure Legends
View article: Supplementary Figure 5 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 5 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 5
View article: Supplementary Figure 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 2 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 2
View article: Supplementary Figure 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 1 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 1
View article: Supplementary Figure 3 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 3 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 3
View article: Supplementary Figure 7 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
Supplementary Figure 7 from KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer Open
Supplementary Figure 7
View article: Psychological Barriers and Perceptual Drivers of Sensor-Based Smart Health Technology Adoption
Psychological Barriers and Perceptual Drivers of Sensor-Based Smart Health Technology Adoption Open
Smart health technologies integrating radar sensors enable non-invasive, real-time health monitoring and are central to future-oriented healthcare systems. However, psychological and perceptual barriers may hinder their adoption. This stud…
View article: Single-cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway
Single-cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway Open
Bacillus Calmette-Guérin (BCG) is the mainstay of treatment for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC), yet recurrence rates remain high. To improve the efficacy of BCG, a better understanding of the immune …
View article: Arterial Embolization versus Robotic Partial Nephrectomy for the Treatment of Renal Angiomyolipomas
Arterial Embolization versus Robotic Partial Nephrectomy for the Treatment of Renal Angiomyolipomas Open
Objective: To compare the outcomes of robotic-assisted partial nephrectomy (RALPN) and selective arterial embolization (SAE) for the treatment of sporadic renal angiomyolipoma (AML). Patients and methods: The outcomes of patients who were …
View article: Partial Cystectomy for Muscle-Invasive Bladder Cancer
Partial Cystectomy for Muscle-Invasive Bladder Cancer Open
Partial cystectomy is a surgical bladder-sparing option for selected patients with muscle-invasive bladder cancer (MIBC), urachal adenocarcinoma and diverticular bladder tumors. Partial cystectomy hold several advantages. It allows for def…
View article: Heat shock induces alternative polyadenylation through dynamic DNA methylation and chromatin looping
Heat shock induces alternative polyadenylation through dynamic DNA methylation and chromatin looping Open
Alternative cleavage and polyadenylation (APA) is a gene regulatory mechanism used by cells under stress to upregulate proteostasis-promoting transcripts, but how cells achieve this remains poorly understood. Previously, we elucidated a DN…
View article: Missed Follow-Up and Kaposi Sarcoma Progression: The Consequences of Medication Non-adherence
Missed Follow-Up and Kaposi Sarcoma Progression: The Consequences of Medication Non-adherence Open
Kaposi sarcoma (KS) is a serious AIDS-defining malignancy that can progress rapidly in the setting of profound immunosuppression. Non-adherence to antiretroviral therapy (ART) remains a major barrier to viral suppression, particularly amon…
View article: Alternative polyadenylation regulates human urothelial cell differentiation
Alternative polyadenylation regulates human urothelial cell differentiation Open
The urothelium is stratified into progenitor basal cells, intermediate cells, and terminally differentiated umbrella cells. Proper renewal of umbrella cells is necessary for maintaining urinary tract barrier integrity. To investigate wheth…
View article: Single Cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway
Single Cell RNA-sequencing of BCG naïve and recurrent non-muscle invasive bladder cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway Open
Non-muscle invasive bladder cancer (NMIBC) represents 70–80% patients with newly diagnosed bladder cancer, and Bacillus Calmette-Guérin (BCG) remains a cornerstone treatment for intermediate-and high-risk NMIBC to prevent disease recurrenc…
View article: Benign Prostatic Hyperplasia Knowledge Deficits Among Male Urology Patients
Benign Prostatic Hyperplasia Knowledge Deficits Among Male Urology Patients Open
There remain significant knowledge gaps about BPH among men seeking urologic care. Education tools for both patients and primary care physicians may help improve health literacy as well as health outcomes for patients with BPH.
View article: Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.
Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery. Open
Bladder cancer (BLCA) genomic profiling has identified molecular subtypes with distinct clinical characteristics and variable sensitivities to frontline therapy. BLCAs can be categorized into luminal or basal subtypes based on their gene e…
View article: A Forgotten Encounter: A Case of Amebic Liver Abscess Mimicking Hepatic Malignancy in a Non-endemic Region
A Forgotten Encounter: A Case of Amebic Liver Abscess Mimicking Hepatic Malignancy in a Non-endemic Region Open
Amebic liver abscess (ALA), caused by Entamoeba histolytica, is prevalent in endemic regions such as Central/South America, Southeast Asia/India, and Africa but is considered rare in North America. Symptoms of E. histolytica …
View article: Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract Open
Introduction Small cell neuroendocrine carcinoma of the urinary tract (SCNEC‐URO) has an inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate the predictors and patterns of relapse after surgery. Materia…
View article: Exploring the utility of snRNA-seq in profiling human bladder tissue: A comprehensive comparison with scRNA-seq
Exploring the utility of snRNA-seq in profiling human bladder tissue: A comprehensive comparison with scRNA-seq Open
Single cell sequencing technologies have revolutionized our understanding of biology by mapping cell diversity and gene expression in healthy and diseased tissues. While single-cell RNA sequencing (scRNA-seq) has been widely used, interest…
View article: Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model Open
Introduction Nadofaragene firadenovec (Ad-IFNα/Syn3) is now approved for BCG-unresponsive bladder cancer (BLCA). IFNα is a pleiotropic cytokine that causes direct tumor cell killing via TRAIL-mediated apoptosis, angiogenesis inhibition, an…
View article: A Tale of 2 Troubling Tachycardias
A Tale of 2 Troubling Tachycardias Open
View article: Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder
Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder Open
NeoCTX had suggestive benefit in patients with cT1 bladder SCNEC with decreased odds of pathologic upstaging, metastatic relapse, and improved survival.
View article: Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer
Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer Open
In this cohort with LA-MIBC treated with RT, distant failures predominate, local failures are less common, and toxicity was minimal. Survival outcomes remain encouraging for RT in this challenging patient population. Further investigation …
View article: Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer Open
Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-basal/squamous (BASQ) tumors and luminal tumors. Since Pparg has low or undetectable expression in BASQ tumors, we tested the effects of rosiglitazone, Pparg agoni…
View article: Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer
Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer Open
Re-review of TURBT pathology by a dedicated GU pathologist led to change in AUA NMIBC risk stratification in over one-fifth of patients, with potential for changing management.